

Contents

1 Cancer Immunotherapy Confers a Global Benefit	1
Zahra Aryan, Håkan Mellstedt, and Nima Rezaei	
1.1 Introduction	1
1.2 Incidence, Morbidity, and Mortality of Cancers: Why Is a New Therapeutic Avenue Indicated?	2
1.2.1 Cancer Incidence	2
1.2.2 Cancer Mortality Rate	4
1.2.3 Burden of Cancers	6
1.3 History of Immunotherapy of Cancers	9
1.4 Immunotherapy Is Going Upstream to Combat Cancers.	11
1.4.1 Prophylactic Implication of Immunotherapy	13
1.4.2 Therapeutic Implication of Immunotherapy	15
1.5 Strategies of Cancer Immunotherapy.	15
1.5.1 Immunotherapy Acts to Eliminate Immunosuppression	19
1.5.2 Immunotherapy Boosts the Antitumor Immune Responses and Enhances Killing of the Tumor Cell.	20
1.6 At Which Line of Treatment?	22
1.7 Monotherapy or Combined Therapy?	24
1.8 Monitoring the Immunological and Clinical Responses to Immunotherapy	25
1.9 Limitations of Cancer Immunotherapy	25
1.10 Supportive Therapy	26
1.11 Effect of Immunotherapy on Health-Related Quality of Life of Cancer Patients	26
1.12 Cost-Effectiveness of Cancer Immunotherapy	27
1.13 Concluding Remarks	27
References	28
2 Vaccination in Human Solid Tumors: Recent Progress in the Clinical Arena.	41
Giorgio Parmiani, Carolina Cimminiello, Cristina Maccalli, and Vincenzo Russo	
2.1 Introduction	41
2.1.1 Preclinical Rationale	41

2.2	Formulations Used in Cancer Vaccines	42
2.2.1	Peptide-/DC-Based Vaccination Against Cancer	43
2.3	Factors That May Impair the Immune Response Against Tumors	43
2.4	New More Successful Clinical Studies of Vaccination in Cancer Patients	44
2.5	Combination Trials	45
2.6	Concluding Remarks	45
	References	45
3	Immunotherapy for Pediatric Solid Tumors	47
	Lisa M. Kopp and Emmanuel Katsanis	
3.1	Introduction	47
3.2	Solid Tumors	47
3.2.1	Sarcomas	48
3.2.2	Neuroblastoma	49
3.2.3	Wilms Tumor	50
3.2.4	Hepatoblastoma	51
3.2.5	Systemic Germ Cell Tumors	51
3.3	Immune Therapy and Pediatric Solid Tumors	52
3.3.1	Monoclonal Antibodies or Inhibitor Targeting	52
3.3.2	Adoptive T-Cell Therapy and Chimeric Antigen Receptors	55
3.3.3	Tumor Vaccines	56
3.3.4	Cytokines	58
3.3.5	Activation of Innate Immunity	59
3.3.6	Allogeneic Stem Cell Transplant	60
3.4	Challenges with Immune Therapy in Pediatrics	61
3.5	Concluding Remarks	62
	References	62
4	Immunotherapeutic Strategies for Multiple Myeloma	69
	Michal Bar-Natan, Kenneth C. Anderson, and David E. Avigan	
4.1	Introduction	69
4.2	Immune Therapy for Myeloma: Overcoming Tumor-Associated Immune Suppression	70
4.3	Antibody-Mediated Strategies	70
4.3.1	CS1	71
4.3.2	CD38	71
4.3.3	Interleukin-6 (IL-6)	72
4.3.4	PD-1/PD-L1	72
4.4	Cellular Immunotherapy for Multiple Myeloma	79
4.4.1	Allogeneic Transplantation	79
4.4.2	DC-Based Vaccines as a Platform for Antigen Presentation	79

4.4.3	Myeloma Vaccines: Single-Antigen Approaches . . .	80
4.4.4	Myeloma Vaccines: Whole-Cell Approaches	80
4.4.5	NK Cell Therapy	81
4.4.6	Engineered T Cells.	82
4.5	Concluding Remarks	83
	References	83
5	Immunopathology and Immunotherapy of Myeloid Leukemia	93
	Sylvia Snauwaert, Bart Vandekerckhove, and Tessa Kerre	
5.1	Introduction	93
5.2	Immunopathology of Acute Myeloid Leukemia	93
5.2.1	Causes of Genetic Alterations	94
5.2.2	Genes Affected in AML.	94
5.2.3	Models for Leukemogenesis Through Gene Alterations	94
5.2.4	The Leukemic Stem Cell	96
5.2.5	How Do Gene Alterations in the LSC Lead to the Clinical Presentation of AML?	97
5.3	Immunotherapy for AML	97
5.3.1	Antigens to Target in AML	98
5.3.2	Current Immunotherapeutic Strategies for AML.	98
5.4	Concluding Remarks	100
	References	100
6	Immunopathology and Immunotherapy of Lymphoblastic Leukaemia.	105
	Thomas Stübiger and Nicolaus Kröger	
6.1	Introduction	105
6.2	Immunopathology of Lymphoblastic Leukaemia	106
6.2.1	General Considerations	106
6.2.2	Lymphocyte Development as Biological Basis of Disease.	106
6.2.3	Genetics in Acute Lymphatic Leukaemia	106
6.3	Immune Phenotype and Targets in Lymphatic Leukaemia . .	107
6.3.1	Cell Surface Marker.	107
6.3.2	Tumor Antigens	108
6.3.3	Cancer/Testis Antigens	108
6.4	Immunotherapy for Lymphatic Leukaemia	108
6.4.1	Cellular Approaches.	108
6.4.2	Antibodies	110
6.5	Stem Cell Transplantation	111
6.5.1	Allogeneic Stem Cell Transplantation (Allo SCT)	111
6.6	Concluding Remarks	111
	References	112

7 Immunopathology and Immunotherapy of Hodgkin Lymphoma	117
Maryam Ebadi, Yi Zeng, Maria Gkotszamanidou, and Nima Rezaei	
7.1 Introduction	117
7.2 Immunopathology of Hodgkin Lymphoma	118
7.3 General Concepts of Monoclonal Antibodies	122
7.3.1 The Structure of Monoclonal Antibodies	122
7.3.2 Choosing the Optimal Antibody	122
7.4 CD30	123
7.4.1 CD30 Monoclonal Antibodies	124
7.4.2 CD30 mAb-Drug Conjugates	124
7.5 CD20	125
7.5.1 Rituximab	125
7.6 CD40	125
7.6.1 Lucatumumab (HCD122)	126
7.7 CD80	126
7.7.1 Galiximab (IDEC-114)	126
7.8 Therapeutic Efficacy of Cytokines	126
7.8.1 Interleukin-2 (IL-2)	126
7.8.2 An IL-2-IL-12 Fusion Protein Targeting Hodgkin Lymphoma	127
7.9 Bispecific Monoclonal Antibodies	128
7.10 Novel Immunotherapeutic Treatment Strategies in HL	128
7.10.1 Immunotoxins	129
7.11 Concluding Remarks	129
References	129
8 Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma	135
Maryam Ebadi, Nishitha M. Reddy, and Nima Rezaei	
8.1 Introduction	136
8.2 Immunopathology of NHL	136
8.3 CD20	137
8.3.1 Effector Mechanisms of CD20 mAbs	137
8.3.2 Rituximab	138
8.3.3 Targeting CD20 with New Anti-CD20 mAbs	142
8.3.4 First-Generation Anti-CD20 mAb	143
8.3.5 Second-Generation CD20 mAb	146
8.3.6 Third-Generation CD20 mAb	147
8.3.7 Small Modular Immunopharmaceutical Anti-CD20 Protein	147
8.4 CD22	148
8.4.1 Epratuzumab	148
8.4.2 Inotuzumab Ozogamicin (CMC-544)	149

8.5	CD19	149
8.5.1	XmAb5574	149
8.5.2	Blinatumomab (MT102/MEDI-538)	149
8.5.3	hu-DM4/SAR3419	150
8.6	CD30	150
8.6.1	M67	150
8.6.2	SGN-30	151
8.7	CD37	151
8.7.1	Tetulomab (HH1)	151
8.8	CD40	151
8.8.1	Dacetuzumab (SGN-40)	151
8.8.2	Lucatumumab (HCD122, CHIR-12.12)	152
8.9	CD52	152
8.9.1	Alemtuzumab (CAMPATH-1H)	152
8.10	CD80	152
8.10.1	Galiximab (IDEC-I14)	152
8.11	CD74 and HLA-DR	153
8.11.1	Milatumzumab (IMMU-115, hLL1), Naked and Conjugated	153
8.11.2	Apolizumab (Hu1D10, Remitogen)	154
8.11.3	IMMU-114 (hL243g4P)	154
8.11.4	LYM-1	154
8.11.5	Selective High-Affinity Ligands (SHALs)	155
8.12	CD1d and NK Cells	155
8.12.1	CD1d	155
8.12.2	Function of NK Cells in NHL	155
8.12.3	Adoptive Transfer of Highly Cytotoxic NK Cells	156
8.13	Therapeutic Efficacy of Antibody-Targeted Cytokines	156
8.13.1	Interferon- α (IFN- α)	156
8.13.2	Interleukin-2 (IL-2)	157
8.13.3	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)	157
8.14	Novel Immunotherapeutic Treatment Strategies	158
8.14.1	Molecular Engineered Antibodies	158
8.14.2	Radioimmunoconjugates	159
8.14.3	Immunotherapy with Genetically Modified T Cells	161
8.14.4	Genetic Augmentation of Adoptive T Cells	162
8.14.5	Genetic Modifications of NK Cells	163
8.15	Vaccines	164
8.15.1	Salmonella Vaccine	164
8.15.2	DNA Vaccines	165
8.15.3	Epitope-Driven Vaccine Design	166
8.15.4	Preclinical Efficacy of Epitope-Driven DNA Vaccines Against B-Cell Lymphoma	166
8.16	Concluding Remarks	168
	References	168

9	Tumor Immunotherapy of Esophageal and Gastric Cancers	185
	Uhi Toh, Tetsuro Sasada, Ryuji Takahashi, Kyogo Itoh, and Yoshito Akagi	
9.1	Introduction	185
9.2	Current Immunotherapeutic Strategies for Esophageal and Gastric Malignancies	186
9.2.1	Monoclonal Antibody Therapy	186
9.2.2	Adoptive Cell Therapy	187
9.2.3	Dendritic Cell (DC) Vaccination for Esophageal and Gastric Cancers	188
9.2.4	Protein or Peptide Vaccination for Esophageal and Gastric Cancer	190
9.2.5	Personalized Peptide Vaccination (PPV) for Gastric Cancer	192
9.3	Concluding Remarks	192
	References	193
10	Immunopathology of Hepatobiliary Tumors and Immunotherapy of Liver Cancers	199
	Zhen-Yu Ding and Yu-Quan Wei	
10.1	Introduction	199
10.2	Epidemiology	200
10.3	Histology	200
10.4	Immunopathology	201
10.5	Current Therapies	204
10.6	Progress in Immunotherapy	205
10.6.1	Cancer Vaccines	205
10.6.2	Cell Therapy	207
10.6.3	Antibody Therapy	208
10.7	Prospect	210
10.8	Concluding Remarks	211
	References	212
11	Immunology and Immunotherapy of Colorectal Cancer	217
	Rubén Varela-Calviño and Oscar J. Cordero	
11.1	Introduction	217
11.2	Infection and Inflammation	218
11.3	Inflammation, Gut Microbiota, and Colorectal Cancer	220
11.4	Obesity, Metabolic Syndrome, Cancer Cachexia, and Inflammation	221
11.5	CRC Prevention by Nonsteroidal Anti-inflammatory Drugs	223
11.6	Cancer Microenvironment and Immunosuppression	224
11.7	Infiltrating T Cells and Tumor-Associated Antigens	226
11.8	Regulatory Cells and CRC	226

11.9	Immunotherapy for Colorectal Cancer	227
11.9.1	Lymphodepletion and Adoptive Cell Transfer.	227
11.9.2	Monoclonal Antibodies	228
11.9.3	Vaccines	228
11.10	Concluding Remarks	230
	References.	230
12	Immunotherapy of Pancreatic Cancer	237
	Ryan Stevenson, Martin Goodman, and Muhammad Wasif Saif	
12.1	Introduction	237
12.2	Evidence that Pancreatic Adenocarcinoma Elicits Immune Response.	238
12.3	Cellular Targets in Pancreatic Cancer	238
12.4	Immunotherapies in Pancreatic Cancer	238
12.4.1	Active Immunotherapy.	239
12.4.2	Passive Immunotherapy	242
12.5	Radioimmunotherapy.	243
12.6	Immunoconjugates.	243
12.7	Pancreatic Neuroendocrine Immunotherapy	243
12.8	Concluding Remarks	244
	References.	244
13	Immune Modulation by Agents Used in the Prevention and Treatment of Colon and Pancreatic Cancers	249
	Naveena B. Janakiram, Altaf Mohammed, Mark L. Lang, and Chinthalapally V. Rao	
13.1	Introduction	249
13.2	Colorectal and Pancreatic Cancers Remain as Unsolved Health Problems	250
13.3	Immunotherapy: Unsuccessful in Regressing Colorectal Tumors and Pancreatic Tumors	251
13.4	Immune Surveillance and Tolerance During Initiation and Progression of Tumors.	251
13.4.1	Tumor Microenvironment	251
13.4.2	Antitumor Innate and Adaptive Immunity.	252
13.4.3	Immune Responses During CRC.	252
13.4.4	Immune Responses During PDAC.	253
13.4.5	Immunomodulatory Effects of NSAIDs	254
13.5	Immunomodulatory Effects of Statins.	260
13.6	Immunomodulatory Effects of Selective Estrogen Receptor Modulators	262
13.7	Immunomodulatory Effects of Rexinoids	264
13.8	Immunomodulatory Effects of Antidiabetic Agents	264
13.9	Immunomodulatory Effects of Natural Agents	265
13.10	Concluding Remarks	267
	References.	268

14 Immunology of Cutaneous Tumors and Immunotherapy for Melanoma	277
Amene Sagha zadeh, Mahdia Sagha zadeh, and Nima Rezaei	
14.1 Introduction	277
14.2 Skin Immune System	278
14.3 A Dual Perspective: Tumor Immunity	278
14.3.1 Tumor-Associated Macrophages (TAMs): Cause or Effect?	279
14.3.2 Dendritic Cells (DCs): ADL Triangle	279
14.3.3 Lymphocytes: Hero or Bystander or Antihero?	280
14.4 Tumor Antigens	281
14.4.1 Tumor Antigens of Melanoma	281
14.5 Immunosuppression and Skin Tumors	282
14.5.1 Skin Tumor-Induced Immunosuppression	282
14.5.2 Immunosuppression-Induced Skin Tumors	282
14.6 Photoimmunology	283
14.6.1 BRAF-MAPK	284
14.6.2 NF- κ B	284
14.7 Immunogenetics of Skin Tumors	284
14.7.1 p53	285
14.7.2 MMP	285
14.8 Inflammation and Skin Cancers	285
14.8.1 Myeloid-Derived Suppressor Cells (MDSCs)	286
14.8.2 Cytokines	286
14.9 Immunotherapy for Melanoma	286
14.9.1 Adoptive (Passive) Immunotherapy	287
14.9.2 Active Immunotherapy	287
14.10 Concluding Remarks	289
References	290
15 Immunopathology of Head and Neck Tumors and Immunotherapy of Squamous Cell Carcinoma	299
Xu Qian, Andreas M. Kaufmann, and Andreas E. Albers	
15.1 Introduction	299
15.2 Immune Responses in HNSCC	301
15.2.1 Wt p53-Specific T Cells	301
15.2.2 HPV-Derived Antigen-Specific T Cells	302
15.3 Mechanisms of Tumor Immune Evasion	302
15.3.1 Suppression of T Cells in the Cancer-Bearing Host	302
15.3.2 Role of Regulatory T Cells	303
15.3.3 Tumor Immune Escape	304
15.4 Reversing Immune Escape	304
15.5 T Cell Therapies Directed to Cancer Stem Cells	305
15.6 Current Vaccination Strategies	306
15.7 Concluding Remarks	307
References	307

16 Immunotherapy and Immunosurveillance of Oral Cancers: Perspectives of Plasma Medicine and Mistletoe	313
Hans-Robert Metelmann, Thomas von Woedtke, Kai Masur, Peter Hycckel, and Fred Podmelle	
16.1 Introduction	313
16.2 Trapping an Advanced Squamous Cell Carcinoma of the Tongue by Continuously Repeated Peritumoral Injection of Mistletoe Preparation	314
16.3 Concluding Remarks	317
References	317
17 Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas	319
Julie A. Alosi, Scott W. Baldwin, Jacqueline Oxenberg, and Joseph J. Skitzki	
17.1 Introduction	319
17.2 Coley's Toxin and Toll-Like Receptors	319
17.3 Sarcoma Antigens as Targets for Immunotherapy	321
17.3.1 NY-ESO-1	322
17.3.2 SSX	322
17.3.3 ALK	322
17.3.4 HHV8	323
17.4 Preclinical Models of Immunotherapy for Sarcoma	323
17.4.1 Methylcholanthrene (MCA)	324
17.4.2 p53 and NfI	324
17.5 Undifferentiated Pleomorphic Sarcoma	324
17.6 Clinical Applications of Immunotherapy for Sarcoma	325
17.6.1 Adoptive Cell Therapy	325
17.6.2 Sarcoma Immunotherapy of the Future: CTLA-4 and PD-1 Manipulation	327
17.7 Concluding Remarks	328
References	328
18 Immunopathology and Immunotherapy of Central Nervous System Cancer	333
Adam M. Sonabend, Christopher R. Showers, and Richard C.E. Anderson	
18.1 Introduction	333
18.2 Antitumor Mechanisms of the Immune System	334
18.3 Immune Compartment of the CNS	334
18.4 CNS Tumor-Derived Immunosuppression	335
18.4.1 Tumor Cells	335
18.4.2 Glioma Cancer Stem Cells	336
18.4.3 Tumor-Associated Macrophages/Microglia	337
18.4.4 Myeloid-Derived Suppressor Cells	337
18.4.5 Lymphocytes and Regulatory T cells	339
18.5 STAT3 Pathway	339

18.6	Cytomegalovirus in Glioma	340
18.7	Immunoediting in CNS Cancer	340
18.8	Immunotherapy	342
18.8.1	Adoptive Therapy.	342
18.8.2	Vaccination Strategies	343
18.8.3	Immunotherapy Targeting CNS Cancer-Induced Immunosuppression	354
18.9	Concluding Remarks	355
	References.	356
19	Immunotherapy of Lung Tumors	363
	Shahe Boghossian	
19.1	Introduction	363
19.2	Why Immunotherapy?	364
19.3	Antiangiogenic Agents and Monoclonals	364
19.3.1	Ziv-Aflibercept (Zaltrap®)	364
19.3.2	Bevacizumab	365
19.3.3	PD-1 Monoclonal.	367
19.3.4	Cetuximab	368
19.3.5	Ipilimumab.	371
19.3.6	Talactoferrin.	372
19.4	Peptide-Based Vaccines	373
19.4.1	MAGE-3.	373
19.4.2	EGF Vaccines.	374
19.4.3	MUC1 and Stimuvax®	375
19.4.4	Polyclonal Tumor Vaccines	376
19.4.5	Whole-Cell Tumor Vaccines	376
19.4.6	TGFβ2-Antisense+rhGMCSF	378
19.5	Other Treatment Modalities	378
19.5.1	Dendritic Cells	378
19.6	Mutations	378
19.7	Chemoprevention.	379
19.8	Concluding Remarks	380
	References.	380
20	Immunotherapy of Renal and Bladder Cancers	383
	Faouzia Ajili	
20.1	Introduction	383
20.2	Histological subtypes and staging	384
20.2.1	Nonmuscle Invasive Bladder Tumor	384
20.2.2	Invasive Bladder Tumor.	384
20.3	Clinical Use of BCG Immunotherapy for NMIBC	384
20.3.1	History	384
20.3.2	Effectiveness	385
20.3.3	Side Effects	385
20.3.4	Mechanism of the Antitumor Effect	386
20.3.5	Action of BCG.	387
20.3.6	The Role of the Host	387

20.3.7	The Immune Response to Mycobacteria and BCG	387
20.3.8	The Role of Tumors	389
20.3.9	Scheme of Optimal Therapy	390
20.3.10	Predictors of the Outcome of Nonmuscle Invasive Bladder Cancer	390
20.3.11	The Clinicopathological Factors Predicting Recurrence and Progression	390
20.3.12	Grade	390
20.3.13	Stage	390
20.3.14	Multiplicity	391
20.3.15	Gender	391
20.3.16	Age	391
20.4	Markers Predicting Response to BCG	391
20.4.1	Cell Cycle Regulators	391
20.4.2	Apoptotic Markers	392
20.4.3	Angiogenesis Markers	392
20.4.4	Inflammatory Markers	393
20.5	Immunotherapy of Renal Cancer	393
20.5.1	General Treatments for Metastatic Renal Cancer	393
20.5.2	Prognostic Systems in Metastatic Kidney Cancer	395
20.6	Concluding Remarks	395
	References	395

21 Immunopathology of Specific Cancers in Males and Females and Immunotherapy of Prostate and Cervical Cancer 401

Maurizio Chiriva-Internati, Fabio Grizzi, Gianluigi Taverna,
Leonardo Mirandola, Scott W. Dahlbeck, Marjorie R. Jenkins,
Diane D. Nguyen, Martin J. D'Souza, Everardo Cobos,
and Jose A. Figueroa

21.1	Introduction	401
21.2	Prostate Cancer: Past, Present, and Future	402
21.3	Immunotherapy of Prostate Cancer	403
21.4	Cervical Cancer: What We Know and What We Need to Know	405
21.5	The Immunotherapy of Cervical Cancer	406
21.6	Concluding Remarks	407
	References	408

22 Immunology and Immunotherapy of Ovarian Cancer 413

Jacek R. Wilczyński and Marek Nowak

22.1	Introduction	413
22.2	The Role of Cytokines in Neovascularization of Epithelial Ovarian Cancer (EOC)	414
22.2.1	Characterization of VEGF Function	414

22.2.2	VEGF in Ovarian Cancer Patients	415
22.2.3	Role of VEGF for Ovarian Cancer Growth, Dissemination, and Metastases	415
22.3	The Role of Pro-inflammatory Cytokines in Ovarian Cancer	416
22.3.1	Inflammation and Cancer: General Remarks	416
22.3.2	Inflammatory Reaction and the Risk of Ovarian Cancer	418
22.3.3	Inflammation and Ovarian Cancer Growth and Dissemination	419
22.4	Regulatory and Inflammatory Cells in Ovarian Cancer	428
22.5	Cytokines in Diagnosis and Prognosis of Ovarian Cancer	431
22.5.1	Diagnosis	431
22.5.2	Prognosis	432
22.6	Immunotherapy of Ovarian Cancer	432
22.6.1	Monoclonal Antibodies	433
22.6.2	Cytokines	436
22.6.3	Dendritic Cells	437
22.7	Concluding Remarks	437
	References	437
23	Immunology and Immunotherapy of Breast Cancer	457
	John Stagg and Sherene Loi	
23.1	Introduction	457
23.2	CD8 ⁺ T Cells	458
23.3	CD4 ⁺ and FOXP3 ⁺ T Cells	458
23.4	CD4 ⁺ Follicular Helper T Cells	459
23.5	B Cells in BC	459
23.6	Macrophages and MDSC in BC	459
23.7	Immune Infiltrates, Gene Signatures, and BC Subtypes	460
23.8	Effect of Chemotherapy on Tumor Immunity	460
23.9	Targeted Therapies (Including Trastuzumab and Tyrosine Kinase Inhibitors).	461
23.10	Immunotherapy of Breast Cancer	462
23.10.1	MUC-1 Vaccines	462
23.10.2	HER2 Vaccines	462
23.10.3	MAGE-A3 Vaccines	462
23.10.4	Targeting Immune Checkpoints	462
23.10.5	Anti-CTLA-4	463
23.10.6	Anti-PD-1	463
23.10.7	Combination of Checkpoint Inhibitors	464
23.10.8	Agonistic of TNF Receptor Superfamily	465
23.10.9	Blocking the Immunosuppressors	465
23.10.10	Adoptive T Cell Therapy	466
23.11	Concluding Remarks	466
	References	467

24 Immunology and Immunotherapy of Graft-Versus-Host Disease	471
Doreen Haase	
24.1 Introduction	471
24.2 GVHD	472
24.3 Pathogenesis of Acute GVHD	472
24.3.1 Phase I: Conditioning	472
24.3.2 Phase II: Activation	474
24.3.3 Phase III: Effector Phase	474
24.4 Natural Control of GVHD	475
24.5 Graft-Versus-Tumor Effect	475
24.6 Prevention of GVHD	475
24.7 Treatment of Acute GVHD	476
24.8 Targeted Approaches	476
24.8.1 Targeting Cytokines	476
24.8.2 Targeting Co-stimulation	477
24.8.3 Targeting Cell Subsets	477
24.9 Concluding Remarks	479
References	479
Index	487